Literature DB >> 3908616

Respiratory syncytial virus infection in immunosuppressed animals: implications in human infection.

D T Wong, M Rosenband, K Hovey, P L Ogra.   

Abstract

Neonatal cotton rats were treated with cyclophosphamide parenterally for three weeks before intranasal inoculation of live respiratory syncytial virus (RSV). Immunosuppressive therapy resulted in severe depletion of lymphocytes from the peripheral circulation, the spleen, and the thymus. In contrast to normal rats, immunosuppressed animals developed severe pulmonary pathology with marked infiltration of foamy macrophages. Persistent degeneration and regeneration of bronchial epithelial cells were also observed, in which RSV antigens could be demonstrated by the immunoperoxidase technique. In addition, large quantities of live virus were recovered from the respiratory tract of these animals for as long as six weeks after infection. Systematic dissemination of RSV, which has never been documented in immunocompetent control rats, was found in four of the cyclophosphamide-treated animals. These results support clinical observations that cellular immunity may be very important in the pathogenesis of RSV infection in the human host.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3908616     DOI: 10.1002/jmv.1890170408

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  In vivo selection of respiratory syncytial viruses resistant to palivizumab.

Authors:  Xiaodong Zhao; Wayne M Sullender
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis.

Authors:  J B van Woensel; T F Wolfs; W M van Aalderen; P L Brand; J L Kimpen
Journal:  Thorax       Date:  1997-07       Impact factor: 9.139

Review 3.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

4.  Neonatal respiratory syncytial virus infection: role of transplacentally and breast milk-acquired antibodies.

Authors:  D T Wong; P L Ogra
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  Tissue distribution of mucosal antibody-producing cells specific for respiratory syncytial virus in severe combined immune deficiency (SCID) mice engrafted with human tonsils.

Authors:  D Nadal; B Albini; E Schläpfer; C Chen; L Brodsky; P L Ogra
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

Review 6.  Animal models of respiratory syncytial virus infection.

Authors:  Geraldine Taylor
Journal:  Vaccine       Date:  2016-11-29       Impact factor: 3.641

7.  Long-Term Infection and Pathogenesis in a Novel Mouse Model of Human Respiratory Syncytial Virus.

Authors:  Rui Xiong; Rui Fu; Yong Wu; Xi Wu; Yuan Cao; Zhe Qu; Yanwei Yang; Susu Liu; Guitao Huo; Sanlong Wang; Weijin Huang; Jianjun Lyu; Xiang Zhu; Chunnan Liang; Yihong Peng; Youchun Wang; Changfa Fan
Journal:  Viruses       Date:  2022-08-09       Impact factor: 5.818

8.  Cationic liposome-mediated enhanced generation of human HLA-restricted RSV-specific CD8+ CTL+.

Authors:  Innocent N Mbawuike; Yongxin Zhang; Ying Wang; Ling Song
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.542

9.  Host and Viral Factors in Respiratory Syncytial Virus Infection.

Authors:  Peter Mastrangelo; Richard G Hegele
Journal:  Curr Pediatr Rep       Date:  2013-05-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.